about
Obstructive sleep apnoea and related comorbidities in incident idiopathic pulmonary fibrosis.Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study.Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension.Healthcare pathway and patients' expectations in pulmonary fibrosis.Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis.The unmet medical need of pulmonary hypertension in idiopathic pulmonary fibrosis.Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis.Prevalence and characteristics of TERT and TERC mutations in suspected genetic pulmonary fibrosis.Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension.The yin and yang of idiopathic pulmonary fibrosis.Interstitial pneumonia with autoimmune features: Clinical, radiologic, and histological characteristics and outcome in a series of 57 patients.Reply: The ATS/JRS Guidelines on Lymphangioleiomyomatosis: Filling in the Gaps.Combined pulmonary fibrosis and emphysema: bad and ugly all the same?Lung biopsy in interstitial lung disease: balancing the risk of surgery and diagnostic uncertainty.Thoracic manifestations of segmental neurofibromatosis.Safety and efficacy of pirfenidone in patients carrying telomerase complex mutation.Pulmonary arterial hypertension in heroin users.Effect of cladribine therapy on lung cysts in pulmonary Langerhans cell histiocytosis.Pulmonary alveolar proteinosis following cryptococcal meningitis: a possible cause?Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss).Haemodynamics and serial risk assessment in systemic-sclerosis associated pulmonary arterial hypertensionCombined pulmonary fibrosis and emphysema in systemic sclerosis: A syndrome associated with heavy morbidity and mortalityLong-term safety of pirfenidone: results of the prospective, observational PASSPORT study12q13.12q13.13 microdeletion encompassing ACVRL1 and SCN8A genes: Clinical report of a new contiguous gene syndromeImpact of comorbidities and delay in diagnosis in elderly patients with pulmonary hypertensionAir travel and incidence of pneumothorax in lymphangioleiomyomatosisThe challenge of criteria for interstitial pneumonia with autoimmune featuresAcute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisationPhenotype and outcome of PAH patients carrying a TBX4 mutationPredictors of progression in systemic sclerosis patients with interstitial lung diseaseConcomitant medications and clinical outcomes in idiopathic pulmonary fibrosisClinical phenotypes and outcomes of precapillary pulmonary hypertension of sickle cell diseaseSurvey of Physician's Knowledge, Attitudes, and Practices Regarding Idiopathic Pulmonary Fibrosis in TurkeyRegulator of telomere length 1 (RTEL1) mutations are associated with heterogeneous pulmonary and extra-pulmonary phenotypesTreatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseasesTargeting interleukin-13 in idiopathic pulmonary fibrosis: from promising path to dead endPatients' and Healthcare Professionals' Experiences of Idiopathic Pulmonary Fibrosis Treatment with the Pirfenidone 801 mg Tablet Formulation: A Multinational SurveyThe natural history of progressive fibrosing interstitial lung diseasesRisk factors for disease progression in idiopathic pulmonary fibrosisPresentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases
P50
Q38735329-2702AE79-3B84-4D46-A75F-C926E8877886Q40501212-B08F030D-7930-4020-9E86-508B7E505FBCQ41357641-C4603EBF-6FE3-4C80-B671-3ADA73CF29A8Q41384468-F98A8038-2F25-4BD8-8D44-90187EFD8B38Q43995291-68C4E916-4ACB-47D7-8A5D-002E9D690AF8Q47653464-B0F2BB23-6DC7-48EB-8816-983F8683080AQ47688581-0E0920B4-F34F-4B7C-86B2-E84A780385F8Q47699201-66F0F89B-4527-4E08-99DF-1249905E1175Q47757216-0F694953-D544-4B74-9B09-3430F359D308Q47966352-C85C9579-C79B-4997-BB58-668559966305Q47987071-258DBC0E-91A9-4541-9541-C00B2961F485Q48134309-DB911737-313C-40B5-A1A3-FDA8D3AC3AA0Q48172521-653B3786-1BB9-4DC0-AF15-83C6250E8D42Q48258321-D3CDC96A-A99C-4109-A707-AA7A9FB058C0Q48284474-971E6F6E-1C6A-408E-8237-76B6CC4ECF8AQ49960065-ACD69FD0-ED4D-4005-9A25-C8D153235602Q51525620-DDF454C6-45B0-4086-A3A0-444A3DD86EB2Q53840508-033D1AFD-9510-4166-84EE-357CF74F7704Q54246643-427E0B6E-9599-482C-817E-C5F33306762FQ54777184-8B493234-1A24-4C45-A1FE-DEF1A5532EBFQ56977551-7788BAAD-0899-41FB-AD1F-8F940337015EQ58423136-733CB635-2577-469E-9B40-4A1DE500B960Q58587295-8F810258-B300-48BC-B715-8E6890F25323Q58591381-B053B872-0517-4931-83E3-FF3FFADD31FEQ59804472-06EEF2B2-CD23-4917-BB7E-F39763AB1AA5Q60045100-9500B137-2A96-44A3-93D1-8FA4EC2FAD41Q87849343-9D511713-0629-48A3-8EBE-D1C2314986E9Q89721817-9152740E-BB26-4765-BED7-B63515D20DE6Q89807935-AAF6D5BA-F157-4DD7-B2CB-EE23F4DEEC36Q89807964-6CA125A1-4DB0-43DA-884E-36B5C2212F60Q90182603-682438D9-E9F3-4ECE-B20F-5D56D5848AF0Q90182625-C0762F9E-B889-4B22-972A-D2BDCDBA0512Q90262104-74C2EF70-E1CE-4EC1-8563-A1A690511AC6Q90317197-8E3AFFDF-2D96-440B-8836-D6A29C27768EQ90439965-A61C0276-F13E-4664-A1F1-F56A8CA86F42Q90463119-9D28BA7C-0604-4F23-B7A8-2C7CF524ED9FQ90473360-807DF2B3-8BC3-4A44-B8C6-52B096498D61Q90689112-FAE2493A-FF44-45D2-979C-91B74AD20734Q90701712-3D90202C-5A19-4E88-B7B4-ECB9FB9ABD64Q90711518-A59780C0-53D9-4E03-9EDC-2964B0213B80
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Vincent Cottin
@ast
Vincent Cottin
@en
Vincent Cottin
@es
Vincent Cottin
@nl
Vincent Cottin
@sl
type
label
Vincent Cottin
@ast
Vincent Cottin
@en
Vincent Cottin
@es
Vincent Cottin
@nl
Vincent Cottin
@sl
prefLabel
Vincent Cottin
@ast
Vincent Cottin
@en
Vincent Cottin
@es
Vincent Cottin
@nl
Vincent Cottin
@sl
P214
P106
P21
P214
P31
P496
0000-0002-5591-0955
P735
P7859
lccn-n2015184416